IPR In Cross-Border Biotech Patent Disputes.
✅ 1. What Makes Cross-Border Biotech Patent Disputes Unique?
Biotech patents involve living organisms, genes, antibodies, cell lines, CRISPR, biologics, vaccines, and diagnostic methods. Cross-border disputes become complex because:
Key Challenges
✔ Different patent laws and standards (e.g., US vs. EU vs. India)
✔ Jurisdiction issues (where to sue?)
✔ Different regulatory pathways (FDA vs. EMA vs. CDSCO)
✔ Patentability of life forms
✔ Enforcement issues (injunctions, export bans, licensing)
✔ Compulsory licensing & public health exceptions
✔ Parallel imports and exhaustion doctrines
✅ 2. Core Legal Concepts in Cross-Border Biotech IPR
A. Patent Eligibility
Whether a biotech invention is patentable (e.g., genes, natural products, diagnostic methods)
B. Novelty & Inventive Step
Is the biotech invention new and non-obvious?
C. Enablement & Written Description
Can the invention be practiced by a skilled person?
D. Claim Scope & Doctrine of Equivalents
How broadly can claims be interpreted?
E. Jurisdiction & Forum Shopping
Which country’s court is appropriate?
✅ 3. Key Cases (More Than 5) with Detailed Explanation
🔹 Case 1: Diamond v. Chakrabarty (US, 1980)
Facts
Dr. Chakrabarty engineered a bacterium that could digest crude oil.
Patent application was rejected because living organisms were considered non-patentable.
Issue
Is a genetically engineered microorganism patentable?
Holding
The Supreme Court ruled yes, a genetically modified bacterium is patentable because it is human-made and not naturally occurring.
Significance
Landmark case establishing patent eligibility for genetically modified organisms.
Set precedent for biotech patents worldwide.
🔹 Case 2: Association for Molecular Pathology v. Myriad Genetics (US, 2013)
Facts
Myriad held patents on the BRCA1/BRCA2 genes and their use in breast cancer testing.
Plaintiffs argued genes are products of nature and not patentable.
Issue
Are isolated human genes patentable?
Holding
The Supreme Court ruled:
Natural DNA is not patentable.
cDNA (synthetic DNA) is patentable.
Significance
Changed global standards on gene patenting.
Strengthened public access to genetic testing.
🔹 Case 3: Eli Lilly v. Novartis (India, 2014)
Facts
Eli Lilly held a patent on pemetrexed (Alimta).
Novartis challenged the patent, claiming it lacked inventive step and was not sufficiently disclosed.
Issue
Is the patent for a drug molecule patentable under Indian law?
Holding
Indian Supreme Court denied patent due to lack of inventive step and insufficient disclosure.
Significance
Strong example of India’s strict patentability standards, especially for pharmaceuticals.
Shows how cross-border companies may lose patent protection in certain jurisdictions.
🔹 Case 4: Merck v. Integra (US, 2005)
Facts
Integra had patents on peptide sequences used to inhibit integrins.
Merck used the peptide for research and drug development.
Issue
Does the research exemption allow using patented materials for drug discovery?
Holding
The Supreme Court ruled research exemption is narrow and does not automatically apply to drug discovery unless use is purely for academic research.
Significance
Limits “safe-harbor” for research.
Affects cross-border biotech collaborations and clinical trials.
🔹 Case 5: Novartis AG v. Union of India (India, 2013)
Facts
Novartis applied for a patent for Gleevec (imatinib).
Indian patent law includes Section 3(d), restricting patents for incremental modifications.
Issue
Is imatinib mesylate patentable as an improvement?
Holding
Indian Supreme Court rejected the patent, stating it was a new form of a known substance without significant efficacy.
Significance
Major case impacting access to affordable medicines.
Shows India’s public health focus over multinational patent protection.
🔹 Case 6: Genentech v. Amgen (US, 2012)
Facts
Dispute over monoclonal antibody patents.
Both parties claimed priority for antibodies targeting the same protein.
Issue
Who has priority and what constitutes “sufficient written description”?
Holding
The court ruled written description must show the inventor had possession of the invention (not just a goal).
Significance
Strengthened written description requirement.
Crucial for biotech patents, where claims are broad and complex.
🔹 Case 7: Roche v. Cipla (India, 2015)
Facts
Roche sued Cipla for making generic versions of cancer drugs.
Cipla argued patents were invalid or not enforceable in India.
Issue
Can Indian courts enforce patents for expensive biologics?
Holding
Indian courts often scrutinize patents and limit enforcement if public interest is affected.
Significance
Highlights patent enforcement challenges in developing countries.
Illustrates cross-border tension between innovation and access.
✅ 4. Cross-Border IPR Strategies in Biotech
A. Jurisdiction Planning
File patents in key markets (US, EU, Japan, India, China)
Consider where manufacturing and sales occur
B. Claim Drafting
Use broad claims for major markets
Use narrow claims in strict jurisdictions
C. Licensing & Technology Transfer
Use cross-licensing to avoid litigation
Build global licensing strategy
D. Regulatory Exclusivity
Use data exclusivity, orphan drug status, and market exclusivity as a supplement to patents
✅ 5. Conclusion
Cross-border biotech patent disputes involve:
Different legal standards
Public health vs. innovation conflicts
Complex scientific claim interpretation
Global enforcement and jurisdictional battles
The above cases show how courts balance patent rights, public interest, and scientific reality.
RELATED Blog
comments